All relevant data are within the paper and its Supporting Information files.

Introduction {#sec005}
============

An infectious disease is considered eliminated in a specific geographical area when its local transmission is interrupted and maintained at zero \[[@pone.0235631.ref001], [@pone.0235631.ref002]\]. In the long term, the economic rationale for eliminating infectious diseases is apparent: if elimination is achieved, a high cost-effectiveness and high benefit-cost ratios compared to continued disease control are guaranteed and constitute the so-called dividend (i.e. the profit of a financial investment) \[[@pone.0235631.ref003]\]. Long-term benefits are the result of the improvement of both health and non-health outcomes, such as management and treatment cost-savings due to reduced cases and deaths, improved productivity and labour supply, increased educational attainment \[[@pone.0235631.ref004]\] and literacy rates \[[@pone.0235631.ref005]\] and higher lifetime earnings and occupation rates \[[@pone.0235631.ref006]\], all contributing to economic growth and socioeconomic development.

While targeting elimination in the long term is desirable---and achievable for several infectious diseases---, the extremely high costs, combined with the uncertainty and associated risk of failure, cast doubts on short-term feasibility and efficiency of elimination strategies \[[@pone.0235631.ref007]--[@pone.0235631.ref010]\]. Equity concerns also factor into decision-making, as during the initial stages of elimination the less challenging and easy to reach areas and/or groups may be targeted, often leaving the most vulnerable and poor population aside \[[@pone.0235631.ref011]\]. Other challenges stem from the fact that disease elimination is a global public good, characterized by the non-excludability and non-rivalry attributes in consumption \[[@pone.0235631.ref012]\]. The 'global public good' concept implies that governments need to coordinate financial mechanisms and boost cooperation at the regional level in order to achieve elimination as a common goal. Importantly, these challenges should not only surface in the last mile preceding the actual achievement of elimination, but be tackled when decisions on control optimization or pre-elimination initiatives are being made.

All the issues above need to be addressed in a context of scarce financial resources and additional pressing public health priorities, where policymakers are faced with key economic questions such as: (1) are the costs associated with investments towards malaria elimination affordable and sustainable in a context of competing health challenges?; (2) is the increased effort associated with implementing interventions towards malaria elimination (with old and/or new interventions and/or strategies) economically justified in comparison with continuing with routine control interventions?

By comparing the incremental costs and health effects of elimination initiatives over time relative to alternative (often business-as-usual) scenarios, cost-effectiveness assessments provide essential instrumental evidence to answer such questions and inform policy-makers on how to best prioritize and allocate limited resources in the short term, while monitoring efficiency of activities towards elimination \[[@pone.0235631.ref013]\].

This debate becomes relevant in the context of malaria, where despite the progress made in the last decades, the burden of disease remains strikingly high, particularly in sub-Saharan Africa (SSA). As a result, the World Health Organization (WHO) Global Technical Strategy for Malaria 2016--2030 (GTS) has urged for the generation of evidence on effective strategies---using available tools---to accelerate progress towards elimination \[[@pone.0235631.ref014]\].

The combination of mass drug administration (MDA) for malaria, consisting of door-to-door administration of antimalarial treatment to every member living in a defined geographical area on the back of existing prevention and treatment tools, has increasingly received attention as a promising strategy to rapidly reduce transmission in low to moderate transmission settings \[[@pone.0235631.ref015]\]. Although MDA was part of control and elimination strategies during the Global Malaria Eradication Programme (GMEP) in the 1950s and --60s, evidence on its effectiveness is limited \[[@pone.0235631.ref016], [@pone.0235631.ref017]\]. Recent studies conducted in Comoros islands, Zambia and South East Asia \[[@pone.0235631.ref018]--[@pone.0235631.ref020]\] have reported that MDA using dihydroartemisinin piperaquine (DHAp) is effective in reducing---although not interrupting---*P*. *falciparum* malaria transmission to unprecedented low levels.

More recently, the Magude project has assessed the feasibility of achieving malaria elimination in an endemic district in southern Mozambique. Following the GTS recommendations \[[@pone.0235631.ref014]\], the project combined an optimized package of existing interventions, including a strengthened surveillance system, case management, intensified vector control with universal long-lasting insecticide treated net (LLIN) distribution and universal (i.e. targeted to all households in the district) indoor residual spraying (IRS), and mass drug administration (MDA) \[[@pone.0235631.ref021]\]. The project was based on direct implementation of malaria interventions and was managed on a learning-by-doing basis, with resources for MDA delivery adjusted over time based on experience accumulation. Effectiveness results of the Magude project align with existing evidence \[[@pone.0235631.ref019], [@pone.0235631.ref020]\], indicating that the package of interventions did not interrupt malaria transmission but drastically reduced malaria prevalence and incidence \[[@pone.0235631.ref022]\].

To date, the debate has largely focused on the impact of MDA on malaria prevalence, but its cost-effectiveness is poorly understood due to the lack of accurate data on costs and resources for MDA campaigns. Scarce short and long-term information is available as either aggregate financial costs from past GMEP elimination experiences, or for very specific settings, such as islands or emergency scenarios \[[@pone.0235631.ref023]\], which limits its use in current programme planning in countries approaching elimination \[[@pone.0235631.ref010]\].

As a result, knowing the short-term costs and benefits associated with strategies involving MDA becomes critical to guide policy-makers in prioritizing and sustaining resources while transitioning from malaria control to malaria elimination. Mozambique is one of the highest malaria burden and weakest link countries in southern Africa, contributing to cross-border transmission and impeding the achievement of a malaria-free status in neighbouring countries \[[@pone.0235631.ref024]\]. Insights on efficient resource allocation become essential for accelerating progress towards malaria elimination at the national and regional level.

In this study, the economic resources and cost-effectiveness of the intervention package implemented in the Magude project are compared with those associated to routine prevention, diagnosis and treatment interventions under routine malaria control (i.e. annual rounds of focal IRS, LLIN distribution and standard case management).

Methods {#sec006}
=======

Study site {#sec007}
----------

Magude district is a rural district in Maputo province, southern Mozambique, with 48,448 identified individuals and 10,965 households, according to a baseline census from 2015. The district has year-round malaria transmission, with seasonal peaks in the rainy season (November--April). Further epidemiological and socio-demographic characteristics of the district have been described elsewhere \[[@pone.0235631.ref022], [@pone.0235631.ref025]\].

The package of interventions deployed at the district level under the Magude project consisted of: a) a strengthened epidemiological surveillance reporting systems established in the district since January 2015; b) annual rounds of universal IRS using DDT and/or pirimiphos-methyl (Actellic,®) between August--October of 2015, and between September--November of 2016, 2017 and 2018; c) two yearly rounds of MDA during two consecutive years, deployed in November 2015 (MDA1), January--February 2016 (MDA2), December 2016 (MDA3) and January--February 2017 (MDA 4) and d) community engagement for MDA to maximize the acceptance of the intervention followed by e) an active surveillance system with focal MDA in the index case household, or reactive focal MDA (rfMDA), starting on June 2017 ([Fig 1](#pone.0235631.g001){ref-type="fig"}).

![Chronogram of activities and interventions of the Magude project, 2015--2018.\
Chronogram of the main malaria elimination interventions implemented in the study district between January 2015 and June 2018, by project year and interventions phase (I and II). MD, mass drug administration; IRS, indoor residual spraying; rfMDA, reactive focal mass drug administration; LLIN, long-lasting insecticidal nets.](pone.0235631.g001){#pone.0235631.g001}

The impact of the interventions was estimated by conducting a before-after study and employing interrupted time series analysis on passively detected weekly malaria cases (by RDT or microscopy) at the health facilities or by community health workers. MDA coverages varied between 58--72% across the four rounds, with children under-five years receiving a higher protection (\>70%) in comparison with population older than five (50--70%). Within three years (August 2015--June 2018), parasite prevalence decreased by 86% and case incidence fell from 195 to 67 cases per 1,000. As a result, an estimated 76.7% of expected cases were averted (38,369 cases averted of 50,005 expected cases had the intervention not taken place) between August 2015 and June 2018. Further details on interventions coverages and effectiveness measurement have been reported elsewhere \[[@pone.0235631.ref022]\].

Study design {#sec008}
------------

We used an incremental approach from the implementer's perspective and compared the costs of the interventions implemented in phase I (between August 2015--2017) and phase II (September 2017--June 2018) of the project ([Fig 1](#pone.0235631.g001){ref-type="fig"}) with the costs of routine malaria control (i.e. counterfactual scenario).

The counterfactual scenario included routine malaria vector control activities implemented by the government, which include annual rounds of focal IRS (i.e. spraying targeted to high-burden areas in the district), universal LLIN distributions during national campaigns every three years, and prompt diagnosis and provision of treatment with efficacious anti-malarial drugs. According to national guidelines \[[@pone.0235631.ref026]\], standard case management is delivered at the health facilities (HF), where malaria testing is performed with rapid diagnostic tests (RDTs) available at all levels, first-line treatment is artemether-lumefantrine (AL) for uncomplicated malaria cases and injectable artesunate for all severe cases.

The interventions planned programmatically by the National Malaria Control Programme (NMCP) that took place in the district simultaneously, including standard case management as well as a national mass distribution of long-lasting insecticidal treated nets (LLIN), were also computed as part of the overall package of interventions within the project ([Fig 1](#pone.0235631.g001){ref-type="fig"}).

Costs and DALYs {#sec009}
---------------

We collected weekly data on the economic resources employed by the project since its inception in 2015 and developed an ingredient-based costing (micro-costing). Regular meetings were held with each area's responsible to list the quantity of resources---economic and financial---utilized in each activity.

Unit costs of purchased resources, disaggregated by commodity and importation price, and in-country delivery costs, were obtained from the procurement department. For non-financial items (i.e. resources used by the project in implementing the interventions that did not involve a financial transaction, such as donated goods or volunteers time), we used data from published literature and country evidence ([S1 Table](#pone.0235631.s005){ref-type="supplementary-material"}). For outsourced activities, such as universal IRS (implemented by GoodBye Malaria to all households in the district), we revised the executed expenditures and organized costing items to fit with our approach.

Costs were depreciated, annualized, inflated, discounted and/or allocated as shared resources according to methodological guidelines \[[@pone.0235631.ref027]--[@pone.0235631.ref029]\] and expressed in constant 2015 US\$ using average yearly exchange and inflation rates \[[@pone.0235631.ref030], [@pone.0235631.ref031]\] ([S1](#pone.0235631.s005){ref-type="supplementary-material"} and [S2](#pone.0235631.s006){ref-type="supplementary-material"} Tables). Our analysis did not consider costs unrelated to the operational aspects of running the project, such as research costs, and merely approximates the costs incurred by the government if the project was to be scaled-up to other areas (see [S1 Text](#pone.0235631.s012){ref-type="supplementary-material"} for details on costing formulas employed).

Cost data associated with routine malaria vector control interventions as part of the counterfactual scenario were gathered from the Global Fund's Price and Quality Reporting database (for LLIN,) and the President's Malaria Initiative country evidence (for IRS) \[[@pone.0235631.ref032]\]. IRS coverage rates (52.2%) registered in the Magude demographic census in 2015 were used to estimate the costs of routine IRS \[[@pone.0235631.ref025]\].

Standard case management costs associated with the Magude project were calculated considering the observed malaria cases across time. In addition, case management costs under the counterfactual scenario were based on the estimated cases had the intervention not taken place. Treatment unit costs included recurrent costs such as personnel, drugs and supplies costs incurred in an outpatient visit. For malaria admission, injectable artesunate treatment and admission costs (assuming an average of 5 days based on expert consultation) were also considered. Treatment unit costs (for outpatients and inpatients) were gathered from a previous study carried out in the district and updated from 2007 to 2015 figures using an inflation rate correction factor \[[@pone.0235631.ref033]\]. Incremental costs are expressed in net terms, as they considered cost-savings due to treating fewer malaria cases under the Magude project scenario.

We translated the estimated number of malaria cases averted associated with the project into DALYs averted. Based on evidence from a neighbouring district hospital, we used the fraction of outpatient visits for malaria that required hospitalization and assumed it to be equivalent to the percentage of malaria cases that derive into severe malaria (even though not all inpatients might have been diagnosed with severe malaria). Evidence on inpatient case fatality rate from the district hospital was used and assumed to reflect the fatality rate of severe malaria cases ([S1 Table](#pone.0235631.s005){ref-type="supplementary-material"}).

DALYs averted were estimated by multiplying the number of DALYs lost from malaria morbidity (severe and non-severe malaria cases) and mortality times the effectiveness of the project on reducing malaria cases and deaths, respectively \[[@pone.0235631.ref028]\]. DALYs were discounted and calculated according to conventional approaches \[[@pone.0235631.ref028]\] (see [S1 Table](#pone.0235631.s005){ref-type="supplementary-material"} for key parameters and sources used in DALYs calculation). Aligned with recent consensus among experts \[[@pone.0235631.ref034]\], DALYs have not been aged-weighted in the analysis.

Data analysis {#sec010}
-------------

The ICER was calculated by dividing the net incremental costs associated with the Magude project by the DALYs averted by the project, when compared to routine malaria control activities under the counterfactual scenario: $$\begin{array}{l}
{ICER = \lbrack\left( {Cost\mspace{360mu} Magude\mspace{360mu} project + Cost\mspace{360mu} case\mspace{360mu} management\mspace{360mu} Magude\mspace{360mu} project} \right) - (Cost\mspace{360mu} routine} \\
{control + Cost\mspace{360mu} case\mspace{360mu} management\mspace{360mu} routine\mspace{360mu} control){\rbrack/\lbrack}DALYs\mspace{360mu} associated\mspace{360mu} Magude\mspace{360mu} project–} \\
{DALYs\mspace{360mu} associated\mspace{360mu} routine\mspace{360mu} control\rbrack} \\
\end{array}$$

To capture potential economies of scale and scope, we estimated the ICER at three different timepoints: i) by end year 1, after the deployment of MDA1 and MDA2 (August 2015--February 2016); ii) by end year 2, after the deployment MDA3 and MDA4 (August 2015--February 2017) and iii) by end year 3, one year after the discontinuation of MDA (August 2015--June 2018).

We varied specific parameters to assess their contribution to overall outcomes, understand key costing drivers and take into consideration univariate uncertainty ([S3 Table](#pone.0235631.s007){ref-type="supplementary-material"}). We built a basic alternative scenario in which several parameters were adjusted in order to estimate the costs of the project if it was implemented by the government. The Magude project implemented from a governmental perspective consisted in adjusting wages and per diems to those paid by the MoH---according to the corresponding health professional category \[[@pone.0235631.ref035]\]---and in considering the use of already existing capital goods within the public health system (i.e. vehicles, warehouses and health structures) and applying the corresponding depreciation rate, instead of being computed as a purchase or rental. A deterministic threshold sensitivity analysis was performed to estimate the minimum number of cases averted for the Magude project to be considered cost-effective.

Joint parameter uncertainty was considered by expressing all model inputs as probabilistic according to appropriate distribution functions \[[@pone.0235631.ref036]\], with assumed uncertainty range of 20% applied to each parameter point estimate, except for parameters for which specific evidence on uncertainty ranges was available ([S1 Table](#pone.0235631.s005){ref-type="supplementary-material"}), and conducted Monte Carlo simulations (1,000 iterations).

Probabilistic results were plotted in a cost-effectiveness plane. To define the Magude project as cost-effective in comparison with routine malaria control (counterfactual scenario), we primarily used standard cost-effectiveness thresholds, based on thresholds of one (highly cost-effective) to three times (cost-effective) the Mozambican gross domestic product (GDP) per capita \[[@pone.0235631.ref037]\], averaged across the period of study. We also graphically represented our results as acceptability curves, which show the probability of the project of being cost-effective for different willingness to pay values, and compared our ICER results with alternative thresholds based on the health opportunity cost \[[@pone.0235631.ref038]\].

A long-term scenario was built by extending both the Magude project and counterfactual scenario costs to 2030. In this modelling exercise, we assumed that the malaria incidence levels achieved by the project would be maintained with continued vector control and rfMDA as implemented during the third year. Malaria routine activities and incidence in the counterfactual scenario were assumed to remain stable over time. Malaria incidence figures were adjusted for population growth rates \[[@pone.0235631.ref039]\] (see [S2 Text](#pone.0235631.s013){ref-type="supplementary-material"} for details).

Results {#sec011}
=======

The economic cost of the Magude project over 3 years was \$4.33 million, with the four rounds of MDA being the most resource intense activity, accounting for 53% of overall resources. With the inclusion of case management costs, at an outpatient and inpatient cost of \$1.7 and \$175, respectively, per malaria episode treated, total economic project costs amounted to \$4.83 million ([Table 1](#pone.0235631.t001){ref-type="table"}).

10.1371/journal.pone.0235631.t001

###### Costs of the Magude project vs counterfactual scenario (routine malaria control).

![](pone.0235631.t001){#pone.0235631.t001g}

  Activity                                                            The Magude project   Counterfactual Scenario   Difference      Comments        
  ------------------------------------------------------------------- -------------------- ------------------------- --------------- --------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Epidemiological surveillance                                        326,260              8%                        \-              326,260         
  Mass Drug Administration                                            2,297,626            53%                       \-              2,297,626       
  Community engagement (for MDA)                                      224,981              5%                        \-              224,981         
  Universal IRS                                                       1,243,128            29%                       \-              1,243,128       IRS implemented by the Magude project, targeted to all households in the district. It achieved operational coverages higher than 90% \[[@pone.0235631.ref023]\]
  Focal IRS                                                           \-                   \-                        473,836         -473,836        IRS implemented by the NMCP, targeted to households in high-burden areas of the district. It achieved coverage rates of 52.2% \[[@pone.0235631.ref033]\]. PMI reference unit costs \[[@pone.0235631.ref032]\]
  rfMDA                                                               186,746              4.31%                     \-              186,746         
  Universal LLIN distribution [\*](#t001fn002){ref-type="table-fn"}   54,168               1.25%                     54,168          0               Mass LLIN distribution planned programmatically by the NMCP in December 2017
  **Sub-total**                                                       **4,332,909**                                  **528,005**     **3,804,904**   
  Case management costs[\*](#t001fn002){ref-type="table-fn"}                                                                                         
   Outpatient                                                         35,761                                         101,444         -65,684         Cost savings due to reduced burden of disease under the Magude Project
   Inpatient                                                          462,308                                        1,311,456       -849,149        
  **Total costs (net)**                                               **4,830,977**                                  **1,940,905**   **2,890,072**   
  malaria cases                                                       20,889                                         59,257          **38,369**      Averted malaria cases Magude project
  DALYs                                                               1,726                                          4,897           **3,171**       Averted DALYs Magude project
  **ICER (deterministic)**                                                                                                           **912**         USD\$ / DALY averted

MDA, mass drug administration; IRS, indoor residual spraying; rfMDA, reactive focal mass drug administration; LLIN, long lasting insecticidal nets; NMCP, national malaria control programme; Contr, contribution; Ref, reference. Costs in constant US\$ 2015.

\* Interventions planned programmatically by the NMCP

Main costing drivers across activities were personnel (39%) and transportation (22%) resources, followed by malaria drugs and other supplies (19%) ([S4 Table](#pone.0235631.s008){ref-type="supplementary-material"}). Ten percent of employed resources included non-financial costs. Non-financial costs were especially present in activities implemented at the health facilities level, such as those related to strengthening the surveillance system, given the use of existing resources within the public health system. Aligned with previous experiences from other door-to-door MDA interventions \[[@pone.0235631.ref023]\], the main cost drivers of the community-wide drug administration---with an average cost of \$19.4 per person treated/round---were personnel and transportation. However, MDA costs decreased by approximately 50% every two rounds, as fewer resources (especially those related to personal and transportation) were used in a shorter time span, leading to a drop from \$26 for rounds 1 and 2 to \$13 for rounds 3 and 4 per person treated and per round ([S5 Table](#pone.0235631.s009){ref-type="supplementary-material"}).

When compared to the counterfactual scenario, the Magude project, at a net incremental cost of \$2.89 million, averted a total 38,369 malaria cases and 3,171 DALYs, leading to a deterministic ICER of \$912 per DALY averted ([Table 1](#pone.0235631.t001){ref-type="table"}). In the base case, the ICER was lower than the standard cost-effectiveness threshold (\$1,404/DALY averted), but higher than the threshold of interventions considered highly cost-effective (\$468/DALY averted) \[[@pone.0235631.ref028]\]. Results showed that the project would no longer be cost-effective with less than 24,936 malaria cases averted, equivalent to 2,061 DALYs averted. These figures represent a 35% decrease in effectiveness.

The one-way sensitivity analysis reflected that the ICER is extremely sensitive to the malaria case fatality rate (CFR) ([S3 Table](#pone.0235631.s007){ref-type="supplementary-material"}; [Fig 2a](#pone.0235631.g002){ref-type="fig"}). Changing MDA operational aspects such as fieldworkers' efficiency (in terms of increased number of houses visited per day and per team) and assuming a constant efficacy rate, also resulted in significantly different MDA cost per capita and ICER results. On the other hand, results showed little variation to changes in operational or costing parameters related to IRS implementation ([S2 Table](#pone.0235631.s006){ref-type="supplementary-material"}; [Fig 2b and 2c](#pone.0235631.g002){ref-type="fig"}).

![(a, b, c). Tornado diagram, deterministic sensitivity analysis. The values in the parentheses stand for the lower and higher range over which the parameter was varied. The vertical line represents the baseline value of the outcome being analysed: ICER in Fig 2a, MDA cost per person treated/round in Fig 2b and universal IRS cost/person covered in Fig 2c. The blue bars show the direction and magnitude of change in the outcome of interest, when the input variable is set to its lower range and the red bars show the direction and magnitude of change when the input variable is set to its higher range. See [S1 Table](#pone.0235631.s005){ref-type="supplementary-material"} for further details. DALYs, disability-adjusted life years; MDA, mass drug administration; DHAp, dihydroartemisinin piperaquine; IRS, indoor residual spraying.](pone.0235631.g002){#pone.0235631.g002}

When evaluated over time (by the end of project year 1, year 2 and year 3), the ICER showed a decreasing trend, reflecting decreased marginal costs but also increased marginal effectiveness during the project's implementation timeline ([S1](#pone.0235631.s001){ref-type="supplementary-material"} and [S2](#pone.0235631.s002){ref-type="supplementary-material"} Figs). Adjusting model parameters to reflect the Magude project implementation costs from a governmental perspective (i.e. costs of the same activities when implemented by the NMCP) significantly reduced the costs (by 32%), leading to an ICER below the highly cost-effectiveness threshold (\$441/ DALY averted) ([S6 Table](#pone.0235631.s010){ref-type="supplementary-material"} and [S1 Fig](#pone.0235631.s001){ref-type="supplementary-material"}).

[Table 2](#pone.0235631.t002){ref-type="table"} presents the results from the probabilistic analysis, with an ICER of \$987 (CI95% 968--1,006) per DALY averted (incremental cost of \$2.89 million \[2.86--2.90\] and 3,167 incremental DALYs averted \[3,111--3,223\]), or an equivalent \$75 per malaria case averted.

10.1371/journal.pone.0235631.t002

###### Monte Carlo simulation results of the Magude project.

![](pone.0235631.t002){#pone.0235631.t002g}

                          Differences                                                                             
  ----------------------- ------------------------ ---------------- ------- -------- ------------------ --------- -------
  Magude project end Y1   (1,9181,21--1,933,915)   (277--287)       282     3,417    (7,272--7,556)     7,414     6,979
  Magude project end Y2   (2,855,967--2,875,219)   (1,108--1,148)   1,128   13,668   (2,707--2,811)     2,759     2,590
  Magude project end Y3   (2,862,766--2,896,358)   (3,111--3,223)   3,167   38,374   **(968--1,006)**   **987**   933

The cost-effectiveness plane plots probabilistic results and suggests that even when accounting for parameters' uncertainty, the project could remain cost-effective by end year 3 (June 2018), with 91% of the simulation points concentrated below the cost-effectiveness threshold (\$1,404 per DALY averted) ([Fig 3](#pone.0235631.g003){ref-type="fig"}). The acceptability curves complement this information and show the probability of the project being cost-effective for a range of different willingness to pay values (to be determined based on governmental preferences, availability of resources, etc.) per DALY averted ([Fig 4](#pone.0235631.g004){ref-type="fig"}) or malaria case averted ([S3 Fig](#pone.0235631.s003){ref-type="supplementary-material"}).

![Cost-effectiveness plane.\
This figure plots the incremental costs (Y axis) and the averted DALYs (X axis) from the Magude project after its first year (light blue dots), after its second year (orange dots) and after its third year (red dots). The circle represents the 95% ellipse (the 95% credible interval); the blue dashed line represents the standard high cost-effectiveness threshold equal to one time the gross domestic product per capita (\$468 per DALY averted) and the green line represents the standard cost-effectiveness threshold equal to three times the gross domestic product per capita (\$1,404 per DALY averted). DALYs, disability-adjusted life years.](pone.0235631.g003){#pone.0235631.g003}

![Cost-effectiveness acceptability curve.\
The acceptability curves show the probability that the Magude project is cost-effective (compared to continuing with routine malaria control) across time (by end year 1, year 2 and year 3) for different levels of willingness to pay to avert one DALY (X axis). The vertical lines represent different WTP that can be applied to Mozambique: US\$468 per DALY averted (standard threshold of highly cost-effective intervention; and US\$1,404 per DALY averted (standard threshold of cost-effective intervention). DALYs, disability-adjusted life years.](pone.0235631.g004){#pone.0235631.g004}

Finally, basic long-term costing suggests that, under the assumption that the gains achieved by the Magude project interventions could be sustained through focalized approaches combined with continued vector control and standard case management, as in the third year of the project \[[@pone.0235631.ref040]\], the Magude project would potentially become a cost-saving strategy by 2030, with financial benefits resulting from treating fewer malaria cases exceeding the initial project costs ([S2 Text](#pone.0235631.s013){ref-type="supplementary-material"} and [S4 Fig](#pone.0235631.s004){ref-type="supplementary-material"}).

Discussion {#sec012}
==========

This study shows that the economic cost of the Magude project was substantially higher than the routine malaria control activities that would have otherwise taken place in the district. In spite of higher absolute costs, the project was cost-effective by the end of year 3, with an ICER of \$987 (CI95% \$968--1,006) per DALY averted, a value below the conventional cost-effectiveness threshold of three times the GDP per capita ([S1 Fig](#pone.0235631.s001){ref-type="supplementary-material"}). We estimate that the project would have still remained cost-effective if achieving at least 65% of the effectiveness (i.e. number of cases averted) observed. This suggests that the mix of interventions delivered through the Magude project would potentially remain cost-effective if implemented in less favourable environmental and socioeconomic contexts.

The ICER decreased over time, from \$7,414 to \$987 per DALY averted between the first and third year of interventions. This contradicts the outcome of previous studies showing an increasing ratio when optimized malaria control interventions are added \[[@pone.0235631.ref041], [@pone.0235631.ref042]\]. The ICER in this project decreased as a result of decreasing project costs (at the numerator) and increasing project effectiveness (at the denominator). Taking into consideration that MDA coverage remained relatively constant but adherence to the drug regime decreased between rounds ([S7 Table](#pone.0235631.s011){ref-type="supplementary-material"}), the effectiveness trend may reflect two aspects: (1) the cumulative increasing health effects of the package of interventions implemented and (2) the high effectiveness of continued intensified vector control and rfMDA in maintaining the gains achieved. The increase in effectiveness could also be driven by environmental factors, given that 2015--16 was an unusual dry malaria season, whereas 2016--17 was characterized by particularly high rainfall, which resulted into very low and exceptionally high malaria incidence levels, respectively.

The observed downward cost trend throughout project implementation, on the other hand, can be explained by a reduction in annualised economic MDA costs from round to round (from \$26 to \$13 per person treated) due to the accumulation of know-how (a similar operational coverage was achieved in rounds 3 and 4, employing nearly half of the workforce from rounds 1 and 2), the reduced training needs and an improvement in resource planning and organization \[[@pone.0235631.ref043]\], together with reduced case management and treatment costs. If a longer time span is considered, the ICER better reflects the potential cumulative cost-savings that accrue from reducing the burden of disease ([S4 Fig](#pone.0235631.s004){ref-type="supplementary-material"}).

Direct comparison of our costs estimates with other door-to-door MDA unit costs would not be appropriate, given that available evidence refers to very diverse contexts, epidemiological settings and MDA specific purposes. However, available estimates---ranging from \$1.22 in Sierra Leone to \$14.13 in Comoros Island \[[@pone.0235631.ref023]\]---also reflect a large share of personnel and transportation costs used for MDA. In addition, whilst a decreasing marginal unit cost over time was observed, these estimates reflect the costs associated with the intensification of malaria control efforts, and not necessarily the costs of reaching the last mile of disease elimination. Several studies estimating the costs associated with modelled elimination (or even eradication) found the cost of averting a marginal case to exponentially increase when approaching the last mile \[[@pone.0235631.ref007], [@pone.0235631.ref044]\]. We can speculate that, should such efforts continue in Magude, the unit cost would rise until elimination is achieved.

The use of conventional cost-effectiveness thresholds in economic assessments has been subject to considerable debate. Recent empirical estimates of country-specific opportunity cost suggest significantly lower thresholds for Mozambique (\$ 537 purchasing power parity per DALY averted or \$ 294 unadjusted) \[[@pone.0235631.ref038]\]. If these estimates were considered in this study, the project's cost-effectiveness would be debatable. More importantly, cost-effectiveness thresholds are only simplified indications on what may constitute a poor, good or very good value for money, and these should be used alongside other criteria that reflect a country's affordability and willingness to pay, as well as other dimensions instrumental in the decision-making process (e.g. equity). The acceptability curves provide a broader spectrum for results interpretation within a context of uncertainty and beyond pre-determined thresholds. If the government sought a 95% probability of the Magude project being cost-effective, it should be willing to pay at least \$1,500 per DALY averted.

However, one should be careful with the extrapolation of results to other malaria settings. First, some specific activities that have taken place in the Magude project are not necessarily an integral part of standard core malaria elimination interventions. Such activities may have influenced the project's effectiveness, by steering decisions on key interventions implementation. For example: a) the demographic census facilitated the identification of households and residents in the area, enhancing MDA and IRS operational coverage and b) the studies on insecticide resistance of malaria vectors guided the selection of appropriate insecticides for effective IRS. The cost imputation of these activities to the project would not only be difficult, as those refer to research activities implemented for other purposes (i.e. identifying baseline demographic, epidemiological and entomological indicators from new studies), but also inappropriate, given they are not representative of the activities that would be implemented if the project was replicated at a larger scale. Nonetheless, their inclusion would not have altered our findings significantly, as the associated costs are relatively small. Second, the project was implemented by external organizations, which means that associated resources and costs do not reflect those occurring under an implementation in programmatic mode. To illustrate this, by adjusting salaries to governmental norms and assuming the use of already existing public and governmental infrastructures, the costs would decrease by 32%. If this program were to be equally effective, this would translate to an ICER of \$441 per DALY averted.

In addition, the presence of potential economies of scope may improve the ICER even further. On example are community-based health interventions run by the government as part of the NMCP or other programmes \[[@pone.0235631.ref045]\]. MDA programs are operational in Mozambique for the control and elimination of lymphatic filariasis, schistosomiasis and soil-transmitted helminths since 2011. As a result, the costs per person treated have diminished by 60% and compliance rates have improved since initiation of the program \[[@pone.0235631.ref046]\]. As MDA interventions are scaled-up, economies of scale can be expected as well \[[@pone.0235631.ref047]\]. Recent estimates for neglected tropical diseases point to a cost of less than \$0.5 per person when more than 100,000 people are treated \[[@pone.0235631.ref048]\]. This figure may be achievable for MDA for malaria as well \[[@pone.0235631.ref047]\].

While other economic questions related to equity, scalability, sustainability and financial affordability associated with moving from control to pre-elimination remain unanswered, this study offers solid evidence on the economic rationale for prioritizing resources on innovative strategies that accelerate the progress towards malaria elimination. The micro-costing approach presented here also provides essential evidence on key inputs for costing extrapolation and scenario development in other settings. Despite the initial high costs and volume of resources associated with its implementation, MDA in combination with existing malaria control interventions appears a potentially cost-effective strategy to accelerate towards malaria elimination in low to moderate transmission settings in SSA.

Supporting information {#sec013}
======================

###### ICER evolution (\"direct evidence Magude project\" and \"governmental perspective\").

(DOCX)

###### 

Click here for additional data file.

###### Cumulative malaria cases averted across time (2015--2018).

(DOCX)

###### 

Click here for additional data file.

###### Cost-effectiveness acceptability curve per malaria case averted.

(DOCX)

###### 

Click here for additional data file.

###### Cumulative costs across time, 2015--2030 (US\$ million).

(DOCX)

###### 

Click here for additional data file.

###### Input variables and probabilistic distribution for cost-effectiveness analysis.

(DOCX)

###### 

Click here for additional data file.

###### Allocation of Magude project shared resources.

(DOCX)

###### 

Click here for additional data file.

###### Deterministic sensitivity analysis, parameters inputs and results implications.

(DOCX)

###### 

Click here for additional data file.

###### Economic costs per budget category and activity (2015--2018).

(DOCX)

###### 

Click here for additional data file.

###### MDA costs per budget category and round.

(DOCX)

###### 

Click here for additional data file.

###### The Magude project costs (\"direct evidence Magude project\" vs. \"governmental perspective\").

(DOCX)

###### 

Click here for additional data file.

###### MDA coverage and adherence rates across rounds.

(DOCX)

###### 

Click here for additional data file.

###### Costing formulas.

(DOCX)

###### 

Click here for additional data file.

###### Costs projection assumptions (2015--2030).

(DOCX)

###### 

Click here for additional data file.

We thank the community of Magude and the district authorities for allowing this project to take place. We also thank the Ministry of Health and the National Malaria Control Program for their contribution to the successful implementation of the project. We extend our gratitude to the Global Malaria Program at WHO, for their guidance and technical support. Special thanks go to Dr Edith Patouillard, for her relevant comments and contributions in the revision of the final manuscript.

AL

:   Artemether-lumefantrine

CE

:   Cost-effectiveness

CI

:   Confidence Interval

CISM

:   Centro de Investigação em Saúde de Manhiça

DALYs

:   Disability Adjusted Life Years

DDT

:   Dichlorodiphenyltrichloroethane

DHAp

:   Dihydroartemsinin-Piperaquine

GMEP

:   Global Malaria Eradication Programme

GTS

:   Global Technical Strategy

HF

:   Health Facility

ICER

:   Incremental Cost-effectiveness Ratio

IRS

:   Indoor Residual Spraying

LLIN

:   Long Lasting Insecticidal Net

MDA

:   Mass Drug Administration

MoH

:   Ministry of Health

NMCP

:   National Malaria Control Program

RDT

:   Rapid Diagnostic Test

rfMDA

:   Reactive Focal Mass Drug Administration

SSA

:   sub-Saharan Africa

WHO

:   World Health Organization

10.1371/journal.pone.0235631.r001

Decision Letter 0

Carvalho

Luzia Helena

Academic Editor

© 2020 Luzia Helena Carvalho

2020

Luzia Helena Carvalho

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

5 May 2020

PONE-D-20-09618

Moving towards malaria elimination in Southern Mozambique: cost and cost-effectiveness of mass drug administration combined with intensified malaria control

PLOS ONE

Dear Crivillé,

Thank you for submitting your manuscript to PLoS ONE. After careful consideration, we felt that your manuscript requires revision, following which it can possibly be reconsidered. Although your manuscript was of interest to the reviewer, a significant amount of issues should be clarified including population size, local malaria endemicity, and  the applicability of the findings according to WHO's guidelines.    Finally, the MS should be submitted to a copy-editing process otherwise the readability of the MS is compromised. For your guidance, a copy of the reviewers\' comments was included below 

We would appreciate receiving your revised manuscript by  July 20. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Luzia Helena Carvalho, Ph.D.

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and

<https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

1\. Thank you for including your ocmpeting interests statement; \"The authors have declared that no competing interests exist.\"

We note that one or more of the authors are employed by a commercial company:ICREA, Pg. Lluís Companys

Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.  

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to  PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors [http://journals.plos.org/plosone/s/competing-interests](about:blank)) . If this adherence statement is not accurate and  there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: [http://journals.plos.org/plosone/s/competing-interests](about:blank)

2\. Thank you also for providing the following funding information within your acknowledgements section; \"CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID). The *Magude project* (NCT02914145) was funded by the Bill and Melinda Gates Foundation and Obra Social "la Caixa" Partnership for the Elimination of Malaria in Southern Mozambique (OPP1115265).\"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**
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The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes
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2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: Yes
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\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: No

Reviewer \#2: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: General comments:

This study evaluates the cost-effectiveness of a pilot malaria elimination program in Mozambique called the Magude project. It demonstrates, like other elimination studies, that drastic disease reductions are achieved during active efforts; but unfortunately, these efforts tend to fail in eliminating local transmission and therefore disease burden climbs again once MDA is stopped. Correspondingly, the ICER of the project improved with each MDA round but ultimately did not achieve a highly cost-effective threshold by the end of the project.

Since I am not a health economist expert, but have a great deal of experience with malaria elimination, the methodology of the study design and analysis appear sound and the figures are clear. However, my concerns are two-fold:

1\) the overall manuscript is not clearly written or punctuated such that it was difficult to read

2\) the content may be more appropriate to a malaria-specific journal and less so to the readership of PLOS One.

Undoubtedly, as with all malaria elimination programs it was a great deal of important work and should be published somewhere. I therefore recommend major revision.

Specific points:

Grammar, punctuation and sentence restructuring are required throughout manuscript but here are some examples:

\- The English is a bit stilted, for example "in the long-term" is not a correct expression and is used multiple times (Lines 24, 31). Long-term is an adjective not a noun. Also elimination is maintained "at zero" not "to zero" (line 24) and lines 43-49 are confusing and not clear. This and the next paragraph have only single sentences in them. There are many run-on sentences in intro that impact clarity. Would recommend a thorough read and edit by a native English speaker.

\- Lines 64-67 should be in results or discussion, not intro

\- Lines 96-97 need to use different distinguishers for MDA rounds and time frames - too many short hyphens. Figure 1 is nice and clear.

\- Inappropriate use of hyphen versus em dash throughout (or inconsistent - see lines 199-200)

\- Lines 134-135 \-\-- poorly written and punctuated "Based on the observed malaria cases and the estimated cases expected had the intervention not taken place - the counterfactual-, respectively, we estimated resources..."

\- Line 269 - should be em dashes

\- Line 318 - "Mozambique stands among the weakest link countries" - this does not make sense to use stand in this sentence - Mozambique IS one of the weakest links in southern Africa

Abstract

\- Last sentence of background should be in results

\- Inappropriate use of short hyphens throughout

Introduction/Methods

\- This is called a proof of concept pilot study in abstract but I do not see any Magude Project references or actual descriptions of the study interventions itself aside from Figure 1 and corresponding test. It would be nice to know more to set the stage - e.g. what population was covered, how many people, how many villages within a town/district, etc. Is Magude a town or a province? How big is Magude? Is it more children or adults? Is Magude just someone's name or Portugese term for something? (I know it is a town because I googled it but you see my point).

\- Typically, we call it a pilot if the sample size underpowers the conclusions. I acknowledge that this is a cost-effectiveness study but it would be good to know what was the magnitude of the actual study and its interventions.

Discussion

\- Lines 236-242: first paragraph of discussion should more clearly state main outcome

\- 246-250 is excellently stated but the last sentence at 250-252 should be rephrased using respectively

\- 283-298 should be one paragraph as it is addressing the same issues

\- Why do transportation

\- Line 312 - should be micro-costing

\- Line 318 - you only say sub-Saharan Africa one time so does not need to be acronym

\- Lines 309-320 should be a single concluding paragraph that is tighter and shorter with less run on and repetition

Miscellaneous

\- I am pretty sure that Regina is an MD in addition to an MPH on your author byline

Reviewer \#2: As researchers are in search of the optimal combination of interventions to achieve malaria elimination, in the context of more and more reduced resources, the authors present interesting results contributing to the evidence that a combination of drug-based strategies and intensified control measures could be cost effective. The manuscript is well written and particularly well detailed.

Here are some minor comments for authors' consideration:

Minor comments

• Line 64: "From an economic point of view, this should have translated into improved efficiency over time, reflected in a lower ICER".

This sentence sounds leading and could appear as a speculation on the results. I will suggest removing it

• Line 65: The authors refer to the main trial for further details.

For a better understanding of the context of implementation, the authors should consider adding a brief description of the Magude Project.

• Line 67: the authors state that "the package of interventions..... reduced malaria prevalence by 84.7%." However, it is not mentioned in the manuscript how and when malaria prevalence was measured. The impact measure described in line 132 is a cumulative malaria case incidence.

• Line 80: delete one resource

• Line 82: state the Magude project intervention package here to put in perspective with the counterfactual comparison.

• Methods section:

Related to comment \#2: To put the costs and gains in perspective, it would be important for the reader to know:

o The scale of implementation: is Magude a district? This is not mentioned.

o What is the population size?

o What is the malaria endemicity in Magude

• Line 120: The authors mention "intensified IRS -implemented by GoodBye Malaria".

Is this different from the universal spraying described in lines 92-93 as part of the intervention package? If not, please consider using the same terminology. If it is different, the manuscript should briefly describe how these interventions were implemented in order to help understand the costing aspect and give an idea on how these interventions could potentially be replicated by the programme

• Line 229: The long-term costing does not consider the evidence that the costs of everting a marginal malaria case will increase as malaria transmission declines. As discussed in lines 262-266.

• Line 299: replace "scope" by "scale"

Reviewer \#3: Peer Review: Moving towards malaria elimination in southern Mozambique

General comments

This is a very interesting pilot study on cost-effectiveness for malaria mass drug administration as an additional control strategy in southern Mozambique. The findings have implications for other lower-resource settings, where there is interest in exploring novel implementation approaches for moving towards interruption of transmission and possibly also elimination. It is not fully clear to me whether the specific setting for this pilot study fulfills WHO's recommendation of an elimination setting, and whether this would therefore impact the generalizability of the findings. Close proof-reading of the next draft is necessary -- there are some punctuation, grammatical, and other minor errors. Overall, I commend the authors on the project and hope they are able to continue their investigations, including potential alignment of MDA with NTD MDA efforts as another possible implementation approach.

Specific comments

\- Lines 32-34: Technically, to achieve elimination, all targets would have to be addressed, since transmission would have to stop across the whole geographic area (and thus all populations). Although I agree that equity is a critical point when thinking about the roll-out of strategies towards achieving elimination.

\- Lines 34-35: Not clear why non-excludability and non-rivalry are considered "challenges" or attributes that would create challenges? Surely these are positive attributes, in terms of creating more generalized incentives for elimination?

\- Line 37: The regional consideration is critical, also in terms of how reintroduction of cases from neighboring areas that might not achieve elimination would impact overall cost and effectiveness estimations.

\- Lines 74-78: It is important to note that the WHO does not generally recommend MDA in areas of moderate to high transmission, which may make it more difficult to justify as a policy in areas "transitioning" to malaria elimination (i.e. implying they are not yet at that stage).

\- Line 82: It should be "associated with" not "associated to".

\- Methods: It might be helpful to provide a bit of context about malaria transmission in this setting, to help the reader better understand the timing and approach for the interventions -- is malaria transmission seasonal in this context? If yes, was timing to interventions designed specifically with transmission risk in mind (assuming yes but would be helpful to state clearly)? These factors help determine how optimized implementation was of the different interventions, and thus how the cost-effectiveness ratio might change under different circumstances or in other settings.

\- Line 101/Figure 1: IRS does not seem to appear in Figure 1 as a strategy implemented by the national control programme (no asterisk next to any of the IRS arrows in the Figure) -- is this an oversight, or did the national control programme not deliver any IRS during this time period? If this is the case, line 101 should be revised to reflect this.

\- Lines 106-109: Is there any reason to suspect there might have been differences in the effectiveness (or cost) of standard interventions provided by the national malaria programme as compared to those delivered within the context of the Magude project?

\- Lines 134-136: Slightly awkwardly worded sentence which makes it difficult to understand. Suggest simplifying and removing excess punctuation.

\- Lines 168-171: If additional activities are required though, there could be an argument from the MOH that additional vehicles would be needed (or replacement/maintenance costs would be greater).

\- Lines 186-188: It seems strange to assume that malaria incidence would remain the same for the purposes of the model, if interruption of transmission (and eventual elimination) is the end goal?

\- Lines 208-209: Does this mean that if incidence in the area decreased (fewer potential cases to avert through MDA), the strategy would become less cost-effective? Does not bode well for using it as an elimination strategy, in that case.

\- Lines 210-211: This is a very important point. Do the authors think that it's an indication that providing resources to support earlier case identification (especially of severe cases) as well as patient referral and appropriate treatment would be more cost-effective than MDA?

\- Lines 231-233: But per the Methods, this does not account for reduced incidence of malaria over this time, correct?

\- Lines 281-282: This is a useful observation, from a policy standpoint.

\- Lines 299-304: The idea of potentially integrating malaria MDA into existing NTD strategies (where mapping studies show potential effective population overlap) is very intriguing -- I hope the authors consider this for a future cost-effectiveness study!

Overall, I recommend the manuscript be accepted with minor requested revisions.

\*\*\*\*\*\*\*\*\*\*
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1\. Thank you for including your competing interests' statement; \"The authors have declared that no competing interests exist.\"

We note that one or more of the authors are employed by a commercial company: ICREA, Pg. Lluís Companys

Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

• Response: ICREA is not a commercial employer. It stands for \"Catalan Institution for Research and Advanced Studies\". It is a program launched by the Catalan government to fund researchers (<https://www.icrea.cat/>).

2\. Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

• Response: The same applies as per comment \#1: ICREA is not a commercial affiliation. It stands for \"Catalan Institution for Research and Advanced Studies\". It is a program launched by the Catalan government to fund researchers (<https://www.icrea.cat/>).

3\. Thank you also for providing the following funding information within your acknowledgements section; \"CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID). The Magude project (NCT02914145) was funded by the Bill and Melinda Gates Foundation and Obra Social "la Caixa" Partnership for the Elimination of Malaria in Southern Mozambique (OPP1115265).\"

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Acknowledgments section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form.

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows:

\"The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.\"

• Response: Thank you . We have removed the funding-related text from the manuscript and suggest updating the Funding Statement as follows (this has also been mentioned and included in the cover letter):

"We acknowledge support from the Spanish Ministry of Science, Innovation and Universities through the "Centro de Excelencia Severo Ochoa 2019-2023" Program (CEX2018-000806-S), and support from the Generalitat de Catalunya through the CERCA Program. CISM is supported by the Government of Mozambique and the Spanish Agency for International Development (AECID). The Magude project (NCT02914145) was funded by the Bill and Melinda Gates Foundation and Obra Social "la Caixa" Partnership for the Elimination of Malaria in Southern Mozambique (OPP1115265). The funders had no role in study design, data collection and analysis, decision to

publish, or preparation of the manuscript."

Comments from reviewers

REVIEWER \# 1

General comments:

This study evaluates the cost-effectiveness of a pilot malaria elimination program in Mozambique called the Magude project. It demonstrates, like other elimination studies, that drastic disease reductions are achieved during active efforts; but unfortunately, these efforts tend to fail in eliminating local transmission and therefore disease burden climbs again once MDA is stopped. Correspondingly, the ICER of the project improved with each MDA round but ultimately did not achieve a highly cost-effective threshold by the end of the project.

Since I am not a health economist expert, but have a great deal of experience with malaria elimination, the methodology of the study design and analysis appear sound and the figures are clear. However, my concerns are two-fold:

1- the overall manuscript is not clearly written or punctuated such that it was difficult to read

• Response: We have revised the manuscript writing in detail and it has been proof-read by other co-authors and an external academic so as to ensure the content is clear and understandable to a broad audience.

2- the content may be more appropriate to a malaria-specific journal and less so to the readership of PLOS One. Undoubtedly, as with all malaria elimination programs it was a great deal of important work and should be published somewhere. I therefore recommend major revision.

• Response: The main reason why this manuscript was submitted to PLOS One is that it is part of the Magude Project Special PLOS collection. This collection aims to present a comprehensive vision of different components of the malaria elimination strategy implemented in the Magude project, including the impact on epidemiological, entomological and parasitological outcomes observed during the first and second phase of the project as well as the cost-effectiveness of the mix of interventions. In addition, to our knowledge, PloS One has published a substantial amount of malaria-related (and cost-effectiveness) studies and we think that PloS One is actually read by malaria researchers.

Specific points:

Grammar, punctuation and sentence restructuring are required throughout manuscript but here are some examples:

3- The English is a bit stilted, for example "in the long-term" is not a correct expression and is used multiple times (Lines 24, 31). Long-term is an adjective not a noun. Also elimination is maintained "at zero" not "to zero" (line 24) and lines 43-49 are confusing and not clear. This and the next paragraph have only single sentences in them. There are many run-on sentences in intro that impact clarity. Would recommend a thorough read and edit by a native English speaker.

• Response: We agree with the reviewer. We have worked throughout the document and with the help of different researchers we have proof-read and edit the document in detail. We believe the writing style has significantly improved. Some specific terms -widely used in economics- have been corrected. For example, "the long term" has been changed to "long-term" when used as an adjective -and followed by a noun- and changed to "long term" when "long" is employed as an adjective for "term" (the noun).

4- Lines 64-67 should be in results or discussion, not intro

• Response: We see the reviewers' point. While the effectiveness results of the Magude project will be presented in a separate publication (currently under revision at PLosMed), this study aimed to assess its cost-effectiveness. This is why we thought it was worth mentioning the impact findings in the introduction and provide details of those later in the methods section. More specifically, we have included a "study site" sub-section under methods, describing the context of study, the interventions deployed and the main impact figures achieved.

5- Lines 96-97 need to use different distinguishers for MDA rounds and time frames - too many short hyphens. Figure 1 is nice and clear.

6- Inappropriate use of hyphen versus em dash throughout (or inconsistent - see lines 199-200)

7- Lines 134-135 \-\-- poorly written and punctuated "Based on the observed malaria cases and the estimated cases expected had the intervention not taken place - the counterfactual-, respectively, we estimated resources..."

8- Line 269 - should be em dashes

9- Line 318 - "Mozambique stands among the weakest link countries" - this does not make sense to use stand in this sentence - Mozambique IS one of the weakest links in southern Africa

• Response: We agree with all points above-mentioned (from 5 to 9) and have revised and introduced all suggested changes across the document accordingly as part of the editing process.

Abstract

10- Last sentence of background should be in results.

• Response: Aligned with our answer to reviewer's comment \#4, the effectiveness results are not part of the scope of this study (these are presented in a manuscript currently under revision at PLOS Med (PMEDICINE-D-20-00604R1)), as this paper aims to present the cost-effectiveness results of the project.

11- Inappropriate use of short hyphens throughout

• Response: We have revised the correct use of hyphens vs en dashes vs em dashes across the document as part of the editing process.

Introduction/Methods

12- This is called a proof of concept pilot study in abstract but I do not see any Magude Project references or actual descriptions of the study interventions itself aside from Figure 1 and corresponding test. It would be nice to know more to set the stage - e.g. what population was covered, how many people, how many villages within a town/district, etc. Is Magude a town or a province? How big is Magude? Is it more children or adults? Is Magude just someone's name or Portuguese term for something? (I know it is a town because I googled it but you see my point).

• Response: We agree with the reviewer. We have included a new sub-section under methods (i.e. "Study site") providing some information to set the stage. In addition, we have included two references (see below) which describe in detail the rationale of the project and the epidemiological and sociodemographic context in the district, as well as details on the interventions and study procedures.

References

Galatas, B., Nhacolo, A., Marti, H., Munguambe, H., Jamise, E., Guinovart, C., . . . Sacoor, C. (2020). Demographic and health community-based surveys to inform a malaria elimination project in Magude district, southern Mozambique. BMJ Open, 10(5), e033985. doi:10.1136/bmjopen-2019-033985

Galatas, B., Saúte, F., Martí-Soler, H., Montañà, J., Guinovart, C., Munguambe, H., . . . Aide, P. (2020). The Magude project: a before-after study aiming to eliminate malaria in southern Mozambique. Manuscript under review (PLos Med).

13\) Typically, we call it a pilot if the sample size underpowers the conclusions. I acknowledge that this is a cost-effectiveness study but it would be good to know what was the magnitude of the actual study and its interventions.

• Response: We agree with the reviewer and have not included the concept pilot. In addition, we have included a "study site" sub-section under methods, describing the context of study, the interventions deployed and the main impact figures achieved. We have added information on the district population size in that sub-section as well.

Discussion

14\) Lines 236-242: first paragraph of discussion should more clearly state main outcome

• Response: We have re-written the first paragraph of discussion. It now reads:

(page 16): "This study shows that the economic cost of the Magude project was substantially higher than the routine malaria control activities that would have otherwise taken place in the district. In spite of higher absolute costs, the project was cost-effective by the end of year 3, with an ICER of \$987 (CI95% \$968--1,006) per DALY averted, a value below the conventional cost-effectiveness threshold of three times the GDP per capita (S1 Fig). We estimate that the project would have still remained cost-effective if achieving at least 65% of the effectiveness (i.e. number of cases averted) observed. This suggests that the mix of interventions delivered through the Magude project would potentially remain cost-effective if implemented in less favourable environmental and socioeconomic contexts".

15\) 246-250 is excellently stated but the last sentence at 250-252 should be rephrased using respectively

16\) 283-298 should be one paragraph as it is addressing the same issues

17\) Line 312 - should be micro-costing

19\) Line 318 - you only say sub-Saharan Africa one time so does not need to be acronym

• Response: We have modified the text according to comments 15-19

20\) Lines 309-320 should be a single concluding paragraph that is tighter and shorter with less run on and repetition

• Response: We have modified the last paragraph of the manuscript in the discussion section (page 18):

"While other economic questions related to equity, scalability, sustainability and financial affordability associated with moving from control to pre-elimination remain unanswered, this study offers solid evidence on the economic rationale for prioritizing resources on innovative strategies that accelerate the progress towards malaria elimination. The micro-costing approach presented here also provides essential evidence on key inputs for costing extrapolation and scenario development in other settings. Despite the initial high costs and volume of resources associated with its implementation, MDA in combination with existing malaria control interventions appears a potentially cost-effective strategy to accelerate towards malaria elimination in low to moderate transmission settings in SSA."

Miscellaneous

21\) I am pretty sure that Regina is an MD in addition to an MPH on your author byline

• Response: We have changed accordingly (although later verified the degree abbreviation is not needed according to PLOS ONE formatting requirements.

REVIEWER \#2:

As researchers are in search of the optimal combination of interventions to achieve malaria elimination, in the context of more and more reduced resources, the authors present interesting results contributing to the evidence that a combination of drug-based strategies and intensified control measures could be cost effective. The manuscript is well written and particularly well detailed.

• Response: We thank the reviewer for appreciating the study.

Here are some minor comments for authors' consideration:

Minor comments

1\) Line 64: "From an economic point of view, this should have translated into improved efficiency over time, reflected in a lower ICER". This sentence sounds leading and could appear as a speculation on the results. I will suggest removing it

• Response: We agree with the reviewer. We have removed it.

2\) Line 65: The authors refer to the main trial for further details.

For a better understanding of the context of implementation, the authors should consider adding a brief description of the Magude Project.

• Response: We have removed the sentence from line 65 and provided further details on the project both in the "introduction" (by specifying the interventions included) as well as in a new sub-section included under methods (i.e. "study site"). In this subsection we describe the context of study, the interventions deployed, and the main impact figures achieved.

3\) Line 67: the authors state that "the package of interventions..... reduced malaria prevalence by 84.7%." However, it is not mentioned in the manuscript how and when malaria prevalence was measured. The impact measure described in line 132 is a cumulative malaria case incidence.

• Response: We have removed this effectiveness figure from the introduction and introduced impact estimates only later under the new sub-section "Study site". In addition, it is important to bear in mind that this paper will be part of the Magude Project Special PLOS collection. This collection aims to present a comprehensive vision of different components of the malaria elimination strategy implemented in the Magude project, including the impact of the project on epidemiological, entomological and parasitological outcomes. We have also included the reference of the effectiveness manuscript ---currently under revision at PLOS Med (PMEDICINE-D-20-00604R1) --- were further details can be found on effectiveness outcome measurement and analysis.

4\) Line 80: delete one resource

• Response: Deleted.

5\) Line 82: state the Magude project intervention package here to put in perspective with the counterfactual comparison.

• Response: We have included a description of the intervention package in lines 65-68 Methods section:

6\) Related to comment \#2: To put the costs and gains in perspective, it would be important for the reader to know:

o The scale of implementation: is Magude a district? This is not mentioned.

o What is the population size?

o What is the malaria endemicity in Magude

• Response: We have included information on the epidemiological and demographic characteristics of the district in the first paragraph of a new subsection under methods (i.e. "study site") (lines 90-93). We have also referenced a paper providing further sociodemographic details on the context of study.
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Galatas, B., Nhacolo, A., Marti, H., Munguambe, H., Jamise, E., Guinovart, C., . . . Sacoor, C. (2020). Demographic and health community-based surveys to inform a malaria elimination project in Magude district, southern Mozambique. BMJ Open, 10(5), e033985. doi:10.1136/bmjopen-2019-033985

7\) Line 120: The authors mention "intensified IRS -implemented by GoodBye Malaria". Is this different from the universal spraying described in lines 92-93 as part of the intervention package? If not, please consider using the same terminology. If it is different, the manuscript should briefly describe how these interventions were implemented in order to help understand the costing aspect and give an idea on how these interventions could potentially be replicated by the programme

• Response: Thanks for the comment. We have uniformed terminology and referred to universal IRS (ie. spraying targeted to all households in the district) when referring to the spraying implemented under the Magude project. This is different from the routine IRS that MoH usually does, which is focal IRS targeted to high-burden areas of the district.

8\) Line 229: The long-term costing does not consider the evidence that the costs of everting a marginal malaria case will increase as malaria transmission declines. As discussed in lines 262-266.

• Response: Our scenario assumes that the gains achieved by the third year could be maintained by continuing with a strengthened surveillance and a response system using rfMDA, on top of standard case management, district-wide IRS and LLIN distributions. Given that the approaches to further reduce malaria transmission are not yet clear, it is not possible to provide estimates of the costs of averting marginal malaria cases. Instead, we have only provided indicative figures on the potential cost-savings if health gains can be maintained (without malaria incidence being further reduced but maintained stable) through time. Lines 262-266 are based on findings from other studies and we can only speculate (without direct evidence) on what could be the case in Magude. Importantly, this study is not about the cost-effectiveness of achieving elimination; the study focuses on a phase moving towards elimination.

9\) Line 299: replace "scope" by "scale"

• Response: In this manuscript we have differentiated between "economies of scale" (as the number of people treated increase, cost per treatment decreases ) and "economies of scope"(efficiencies formed by variety, not necessarily by volume). In line 299, when we mention the integration with other community-based health interventions implemented by the government, we refer to "economies of scope". By integrating the delivery of different governmental programs, the unit delivery cost might decrease significantly (shared transport expenses, personnel expenses... and all expenses related to delivering and monitoring the intervention). This would be the case if MDA could be delivered together (integrated) with other door-to-door interventions (i.e. MDA for neglected tropical diseases).

REVIEWER \#3:

General comments

This is a very interesting pilot study on cost-effectiveness for malaria mass drug administration as an additional control strategy in southern Mozambique. The findings have implications for other lower-resource settings, where there is interest in exploring novel implementation approaches for moving towards interruption of transmission and possibly also elimination.

1\) It is not fully clear to me whether the specific setting for this pilot study fulfills WHO's recommendation of an elimination setting, and whether this would therefore impact the generalizability of the findings.

• Response: The Magude project was designed to respond to the call for evidence generation in the World Health Organization (WHO) Global Technical Strategy for Malaria 2016--2030 (GTS). The GTS calls for the generation of evidence to identify new tools and strategies to accelerate towards malaria elimination in malaria endemic areas that already have universal access to vector control and case management. Therefore, the project was not aimed to be conducted in a malaria elimination setting as currently defined by WHO, but rather in a representative malaria-endemic setting of Sub-Saharan Africa (SSA) where reducing malaria morbidity and mortality is most pressing. After establishing an enhanced surveillance system and ensuring near-universal access to care and LLINs, the project used district-wide IRS and MDA to drastically reduce transmission in the area. This was successfully achieved and sustained for at least a year, thus demonstrating that rural areas with stable transmission with SSA can feasibly reduce morbidity to pre-elimination settings in a short period of time through the interventions recommended by WHO.

References

World Health Organization, World Health Organization, Global Malaria Programme. Global technical strategy for malaria, 2016-2030 \[Internet\]. 2015 \[cited 2018 Mar 5\]. Available from: <http://apps.who.int/iris/bitstream/10665/176712/1/9789241564991_eng.pdf?ua=1>

2\) Close proof-reading of the next draft is necessary -- there are some punctuation, grammatical, and other minor errors.

• Response: We agree with the reviewer and this issue has been raised by other reviewers as well. We have revised the manuscript writing in detail and it has been proof-read by other co-authors as well as academics out of the field of malaria so as to ensure the content is clear and understandable to a broad audience.

Overall, I commend the authors on the project and hope they are able to continue their investigations, including potential alignment of MDA with NTD MDA efforts as another possible implementation approach.

• Response: That is indeed very important if MDA for malaria is to be scaled-up in other regions. There are some promising initiatives on integrated mass treatment coverage for neglected tropical diseases in Mozambique that could serve as reference.

Specific comments

3\) Lines 32-34: Technically, to achieve elimination, all targets would have to be addressed, since transmission would have to stop across the whole geographic area (and thus all populations). Although I agree that equity is a critical point when thinking about the roll-out of strategies towards achieving elimination.

• Response: We agree with the reviewer. The Magude project impact paper (currently under revision at Plos Med but part of the same PLOS collection as this manuscript) shows a lot of detail on the spatial and individual-level factors associated with LLIN, IRS and MDA coverage, as well as some characteristics of people who were missed during the MDA. Although equity is a much broader concept, these figures provide a magnitude of the coverage and spatial homogeneity of the interventions. We have provided details on attained coverages at the "study site" section and have referenced the impact paper for further details.

4\) Lines 34-35: Not clear why non-excludability and non-rivalry are considered "challenges" or attributes that would create challenges? Surely these are positive attributes, in terms of creating more generalized incentives for elimination?

• Response: Public goods have the attributes of non-excludability (when ''public'' goods are provided no one can be excluded from their consumption) and non-rivalry in consumption (one person's consumption does not prevent anyone else's). Malaria elimination can be considered also a public good, given that no one in a population can be excluded from benefiting from a reduction in risk of infectious disease when its incidence is reduced, and one person benefiting from this reduction in risk does not prevent anyone else from benefiting from it as well them. Although there is significant benefit to be gained from them by many people, there is no commercial incentive for producing them, since enjoyment cannot be made conditional on payment. As there is no global government to ensure that they are produced and paid for, financial cross border mechanisms need to be created and coordinated. Otherwise, this public good (disease elimination) is under-financed. This is well explained in the referenced paper by Richard D. Smith (2003).
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Smith, R. D. (2003). Global public goods and health. Bulletin of the World Health Organization, 81(7), 475.

5\) Line 37: The regional consideration is critical, also in terms of how reintroduction of cases from neighboring areas that might not achieve elimination would impact overall cost and effectiveness estimations.

• Response: Indeed, especially for a country such as Mozambique, that borders with countries already transitioning from pre-elimination to elimination of malaria (i.e Eswatini, South Africa). In such contexts, elimination of malaria is only possible through strong cross border collaboration (some regional initiatives have already been created, such as MOSASWA).

6\) Lines 74-78: It is important to note that the WHO does not generally recommend MDA in areas of moderate to high transmission, which may make it more difficult to justify as a policy in areas "transitioning" to malaria elimination (i.e. implying they are not yet at that stage).

• Response: The reviewer is correct given that the latest recommendations from WHO on MDA were based on evidence that was generated before 2015. Since then, the WHO has continued to review the evidence generated by several places in Africa where MDA was evaluated in \"high\" and \"moderate\" areas. The results obtained from the Magude project (considered to be a moderate to low area) as well as from other studies, were presented in an Evidence Review Group at WHO, which concluded that MDA could be implemented in moderate transmission areas. However, more evidence was required to make a formal policy recommendation. Therefore, the Magude project, as well as others, aimed to drive this policy change through the generation of operational evidence to inform WHO\'s policies. As answered in our response to comment \#1, the Magude project followed the recommendations proposed by the WHO GTS for Malaria 2016-30, which say that countries or areas with good access to treatment and prevention tools, and a strong surveillance system, should accelerate towards elimination through the use of tools that drastically reduce transmission. The GTS called for evidence on the type of tools that could serve this purpose, among which MDA has been identified as a potential one. Therefore, the Magude project combined existent tools under the premise that the interruption of malaria transmission was biologically plausible when combining MDA with intensified vector control tools. Overall, the study proved that the package of interventions implemented in Magude drastically reduced transmission in a cost-effective way, and these findings may influence WHO and country-based policy.

7\) Line 82: It should be "associated with" not "associated to".

• Response: Modified.

8\) Methods: It might be helpful to provide a bit of context about malaria transmission in this setting, to help the reader better understand the timing and approach for the interventions -- is malaria transmission seasonal in this context? If yes, was timing to interventions designed specifically with transmission risk in mind (assuming yes but would be helpful to state clearly)? These factors help determine how optimized implementation was of the different interventions, and thus how the cost-effectiveness ratio might change under different circumstances or in other settings.

• Response: Agree with the reviewer. Thanks for this. We have included a new sub-section under methods called "study site", where we provide details on the epidemiological context of the district and timing of the interventions.

9\) Line 101/Figure 1: IRS does not seem to appear in Figure 1 as a strategy implemented by the national control programme (no asterisk next to any of the IRS arrows in the Figure) -- is this an oversight, or did the national control programme not deliver any IRS during this time period? If this is the case, line 101 should be revised to reflect this.

• Response: Thanks for the observation. The Magude project included univeral IRS campaigns which were conducted with the project partner Good Bye Malaria (achieving a coverage \>80%). Given universal IRS happened, routine IRS (focal IRS spraying high-burden areas) did not happen. However, the costs of focal IRS have been computed in our counterfactual scenario, given this is what would have happened in the absence of the Magude project. We have revised the writing and clearly differentiated between universal (implemented by the Magude project) vs focal IRS (routine IRS implemented by MoH) across the document as well as in the tables.

10\) Lines 106-109: Is there any reason to suspect there might have been differences in the effectiveness (or cost) of standard interventions provided by the national malaria programme as compared to those delivered within the context of the Magude project?

• Response: Yes, there are differences. As mentioned in comment \#9, apart from the new interventions implemented in the context of the Magude project (i.e. MDA administration), there was an enhancement of the surveillance system, as well as an intensification of vector control tools (i.e. IRS under the Magude project was targeted to all households in the district -universal IRS- while routine IRS deployed by the MoH only targets high burden areas of the district -focal IRS). This translates into different coverage outcomes as well as different costs (see table 1 of the manuscript). The timing of the interventions (done in shorter vs a longer period of time) as well as resources employed for other operational activities (i.e. trainings and supervision visits conducted in better conditions) might have also impacted the quality and effectiveness outcomes associated to the project.

11\) Lines 134-136: Slightly awkwardly worded sentence which makes it difficult to understand. Suggest simplifying and removing excess punctuation.

• Response: We agree and have modified this part accordingly.

12\) Lines 168-171: If additional activities are required though, there could be an argument from the MOH that additional vehicles would be needed (or replacement/maintenance costs would be greater).

• Response: The reviewer is right. In our costing calculations, we do take into consideration the useful life of capital goods (i.e. equipment, transport, infrastructure...) and have imputed maintenance costs. In the case of transport, maintenance costs are directly linked to km travelled. In consequence, an increase in the use of resources (i.e. distances travelled with governmental vehicles) has been reflected in higher maintenance costs.

13\) Lines 186-188: It seems strange to assume that malaria incidence would remain the same for the purposes of the model, if interruption of transmission (and eventual elimination) is the end goal?

• Response: Evidence from the Magude project effectiveness manuscript ---currently being under revision at PLOS Med (PMEDICINE-D-20-00604R1)--- showed that with an intensive implementation of currently available tools recommended by WHO, large reductions in malaria transmission and burden of disease are achieved. However, if elimination is to be achieved in areas of stable transmission (such as the Magude district), new tools and strategies are required. In consequence, it is not yet clear how to achieve elimination in such areas. Through our long-term scenario we wanted to show that, even if elimination is not achieved, if the gains accomplished by the third year could be maintained by continuing with intensified vector control tools together with a strengthened surveillance and a response system using rfMDA, potential cost-savings would arise in the mid and long term. Importantly, this study is not about the cost-effectiveness of achieving elimination; the study focuses on a strategy to efficiently move towards elimination (pre-elimination phase). Text S1 provides details on the costing scenario assumptions.

14\) Lines 208-209: Does this mean that if incidence in the area decreased (fewer potential cases to avert through MDA), the strategy would become less cost-effective? Does not bode well for using it as an elimination strategy, in that case.

• Response: This means that the strategy proved to be cost-effective and that there was still some margin for the strategy to remain cost-effective even if effectiveness decreased. In our case, even if less cases had been averted than those observed, the intervention would remain cost-effective. But up to what point would the intervention remain cost-effective? It would need to avert at least 24,936 cases (a reduction in effectiveness of 35%, given the observed averted cases were 38,369). It actually may be the case that, as the elimination gets closer, elimination activities no longer become cost-effective as the unit cost of averting a marginal malaria case would largely increase. This is one of the challenges of disease elimination in the short-tem (as discussed in the introduction). Certainly, elimination is cost-effective in the long-term.

However, this study is not about the cost-effectiveness of achieving elimination (we don't talk about the costs or cost-effectiveness in the last mile) but rather present the economic rationale of a strategy to efficiently move towards elimination (regardless of not having achieved malaria elimination).

15\) Lines 210-211: This is a very important point. Do the authors think that it's an indication that providing resources to support earlier case identification (especially of severe cases) as well as patient referral and appropriate treatment would be more cost-effective than MDA?

• Response: It is difficult to compare one intervention vs the other. Earlier case identification and management is crucial to control malaria transmission and is considered to be a very cost-effective strategy that any country aiming to transition to pre-elimination stages should have in place. However, additional tools might be needed to further reduce transmission of malaria. This is the case of Magude, where despite having good access to treatment and reasonably effective implementation of vector control and surveillance, further tools (or new combination of already available tools) were needed to further reduce transmission.

16\) Lines 231-233: But per the Methods, this does not account for reduced incidence of malaria over this time, correct?

• Response: Exactly. Following on comment \#13, it is not yet clear how elimination can be achieved in areas of stable transmission (such as in the Magude district), and therefore, it is not possible to provide estimates of the costs of averting marginal malaria cases. Instead, we have provided indicative figures on the potential cost-savings if health gains can be maintained across time. As mentioned earlier, this study is not about the cost-effectiveness of achieving elimination but about a strategy to efficiently move towards elimination (pre-elimination phase).

17\) Lines 281-282: This is a useful observation, from a policy standpoint.

• Response: Thank you for the appreciation.

18\) Lines 299-304: The idea of potentially integrating malaria MDA into existing NTD strategies (where mapping studies show potential effective population overlap) is very intriguing -- I hope the authors consider this for a future cost-effectiveness study!

• Response: We agree with the reviewer and this is an issue that has been raised by other reviewers. If the strategy is to be implemented in a feasible and sustainable way by the government, it will need to be integrated with other community-wide public health interventions. Otherwise, the high volume of resources employed for MDA pose serious doubts on the intervention's scalability.

Overall, I recommend the manuscript be accepted with minor requested revisions.
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If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they\'ll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.
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